# Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2012

- Company: [Standard Biotools Inc.](/companies/lab.md) (CIK 1162194)
- Form: 10-Q
- Filed: 2012-11-09
- Accepted by EDGAR: Nov 9, 2012, 15:41 ET
- Period: 2012-09-30
- Accession: 0001193125-12-463140
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1162194/000119312512463140/d398914d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1162194/000119312512463140/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-07-01 to 2012-09-30 | $12.8m | us-gaap:Revenues |
| Revenue | 9 months, 2012-01-01 to 2012-09-30 | $36.7m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2012-07-01 to 2012-09-30 | $3.5m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2012-01-01 to 2012-09-30 | $11.0m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2012-07-01 to 2012-09-30 | $4.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2012-01-01 to 2012-09-30 | $12.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2012-07-01 to 2012-09-30 | $9.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2012-01-01 to 2012-09-30 | $27.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2012-07-01 to 2012-09-30 | −$3.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2012-01-01 to 2012-09-30 | −$14.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-07-01 to 2012-09-30 | $107.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2012-01-01 to 2012-09-30 | $616.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-07-01 to 2012-09-30 | $61.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2012-01-01 to 2012-09-30 | $101.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-07-01 to 2012-09-30 | −$4.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2012-01-01 to 2012-09-30 | −$15.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-07-01 to 2012-09-30 | −$0.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2012-01-01 to 2012-09-30 | −$0.73 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2012-01-01 to 2012-09-30 | −$14.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2012-01-01 to 2012-09-30 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2012-09-30 | $66.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-09-30 | $105.5m | us-gaap:AssetsCurrent |
| Total assets | at 2012-09-30 | $117.1m | us-gaap:Assets |
| Current liabilities | at 2012-09-30 | $13.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-09-30 | $14.4m | us-gaap:Liabilities |
| Long-term debt | at 2012-09-30 | $0 | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2012-09-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2012-09-30 | $102.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1162194/000119312512463140/d398914d10q.htm

Filed Nov 9, 2012.
Source: SEC EDGAR, the filing index for accession 0001193125-12-463140. Last ingested by Listed: Nov 5, 2026, 21:16 ET. No prices; not investment advice.
